DAVID FRANZBLAU: Open Payments
NPI 1669458576 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$770 in 42 payments from 8 companies in 2025. Trend: 2023 $119 · 2024 $605 · 2025 $770
Food & beverage: $770
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 26 | $429 |
| Alkermes, Inc. | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
Products named: COBENFY, ARISTADA, ABILIFY MAINTENA, Qelbree, INGREZZA, CAPLYTA, UZEDY, AUSTEDO XR.
Industry payments across MI — which companies pay providers there.
